scholarly journals Molecularly-Targeted Therapies in Gynecologic Cancer

2018 ◽  
Vol 5 (1) ◽  
pp. 1-5
Author(s):  
Kathryn Kennedy ◽  
◽  
William Robinson ◽  
Keyword(s):  
Targeted Therapies ◽  
Gynecologic Cancer

Strategic Combination Therapies for Ovarian Cancer

2020 ◽  
Vol 20 (8) ◽  
pp. 573-585
Author(s):  
Xinran Li ◽  
Angel S.N. Ng ◽  
Victor C.Y. Mak ◽  
Karen K.L. Chan ◽  
Annie N.Y. Cheung ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Targeted Therapies ◽  
Cancer Biology ◽  
Gynecologic Cancer ◽  
Antiangiogenic Agents ◽  
Combination Therapies ◽  
Multiple Cancer ◽  
Therapeutic Modalities ◽  
Cancer Pathways ◽  
Effective Combination

Ovarian cancer remains the leading cause of gynecologic cancer-related deaths among women worldwide. The dismal survival rate is partially due to recurrence after standardized debulking surgery and first-line chemotherapy. In recent years, targeted therapies, including antiangiogenic agents or poly (ADP-ribose) polymerase inhibitors, represent breakthroughs in the treatment of ovarian cancer. As more therapeutic agents become available supplemented by a deeper understanding of ovarian cancer biology, a range of combination treatment approaches are being actively investigated to further improve the clinical outcomes of the disease. These combinations, which involve DNA-damaging agents, targeted therapies of signaling pathways and immunotherapies, simultaneously target multiple cancer pathways or hallmarks to induce additive or synergistic antitumor activities. Here we review the preclinical data and ongoing clinical trials for developing effective combination therapies in treating ovarian cancer. These emerging therapeutic modalities may reshape the treatment landscape of the disease.

scholarly journals A Review of mTOR Pathway Inhibitors in Gynecologic Cancer

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Andréia Cristina de Melo ◽  
Eduardo Paulino ◽  
Álvaro Henrique Ingles Garces
Keyword(s):  
Targeted Therapies ◽  
Gynecological Cancer ◽  
Gynecologic Cancer ◽  
Mtor Pathway ◽  
Critical Function ◽  
Cellular Processes ◽  
Wide Range ◽  
Convergence Point ◽  
Attractive Therapeutic Target ◽  
Current Therapies

The treatment of advanced gynecologic cancers remains palliative in most of cases. Although systemic treatment has entered into the era of targeted drugs the antitumor efficacies of current therapies are still limited. In this context there is a great need for more active treatment and rationally designed targeted therapies. The PI3K/AKT/mTOR is a signaling pathway in mammal cells that coordinates important cell activities. It has a critical function in the survival, growth, and proliferation of malignant cells and was object of important research in the last two decades. The mTOR pathway emerges as an attractive therapeutic target in cancer because it serves as a convergence point for many growth stimuli and, through its downstream substrates, controls cellular processes that contribute to the initiation and maintenance of cancer. Aberrant PI3K-dependent signaling occurs frequently in a wide range of tumor types, including endometrial, cervical, and ovarian cancers. The present study reviewed the available evidence regarding the potential impact of some mTOR pathway inhibitors in the treatment of gynecological cancer. Few advances in medical management have occurred in recent years in the treatment of advanced or recurrent gynecological malignancies, and a poor prognosis remains. Rationally designed molecularly targeted therapy is an emerging and important option in this setting; then more investigation in PI3K/AKT/mTOR pathway-targeted therapies is warranted.

scholarly journals Mutational analysis of selected high-grade malignancies in a premenopausal gynecologic cancer population: a potential for targeted therapies?

2018 ◽  
Vol 38 (1) ◽  
Author(s):  
Lauren Pinckney ◽  
Justin Collins ◽  
Christine M. G. Schammel ◽  
Matt Gevaert ◽  
David P. Schammel ◽  
...  
Keyword(s):  
Targeted Therapies ◽  
Mutational Analysis ◽  
Gynecologic Cancer ◽  
High Grade

Evaluating the effect of a group pre-treatment chemotherapy psycho-education session for chemotherapy-naive gynecologic cancer patients and their caregivers

2021 ◽  
Vol 160 (1) ◽  
pp. 234-243
Author(s):  
Diana Samoil ◽  
Nazek Abdelmutti ◽  
Lisa Ould Gallagher ◽  
Nazlin Jivraj ◽  
Naa Kwarley Quartey ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Gynecologic Cancer ◽  
Education Session ◽  
Pre Treatment

Induktion von einem nicht-apoptotischen Zelltodes in der humane Zelllinie HepG2 nach Behandlung mit neuen Targeted Therapies

2019 ◽  
Author(s):  
PI Mester ◽  
E Aschenbrenner ◽  
K Pollinger ◽  
C Kunst ◽  
K Gülow ◽  
...  
Keyword(s):  
Targeted Therapies

Development of hypoparathyroidism due to targeted therapies

2017 ◽  
Author(s):  
Canpolat Asena Gokcay ◽  
Berna Imge Aydogan ◽  
Sule Canlar ◽  
Sevim Gullu ◽  
Murat Faik Erdogan
Keyword(s):  
Targeted Therapies
Sign in / Sign up

Export Citation Format

Share Document